Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.

Anlotinib, an effective choice of third- or later line therapy for patients with refractory advanced NSCLC, provides clinical benefits in terms of PFS, OS, ORR, and DCR. AEs associated with anlotinib were tolerable.